Dolon
- Company typePrivate
- Founded2013
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
Dolon firmographics
Firmographics- Name
- Dolon
- Legal name
- Dolon Ltd
- Website
- https://dolon.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Dolon is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Dolon business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Strategic Consulting Services: Dolon generates revenue by providing strategic consulting services to biopharma clients, including market access strategy, pricing strategy, value development, and policy advisory across the drug lifecycle. Engagements are project-based and consultative in nature.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Dolon product offering
Product offeringCore offering
Dolon is an independent consultancy specializing in strategic pricing and market access for pharmaceutical and biotechnology companies developing rare disease and oncology medicines. The firm delivers five integrated service lines — Value, Access, Pricing, Market Access Policy, and Data & Analytics — through bespoke, project-based engagements that turn complex clinical and reimbursement landscapes into actionable strategies. Following its March 2026 acquisition by Prescient Healthcare Group, Dolon operates as a dedicated Value, Pricing and Access practice serving biopharma clients globally.
Product overview
Dolon is a strategic pricing and market access consultancy, not a software product company. The company offers five integrated consulting service lines: Value, Access, Pricing, Market Access Policy, and Data & Analytics. These services are delivered by specialist consultants to help pharmaceutical and biotechnology companies navigate market access challenges for rare disease and oncology medicines. Following its acquisition by Prescient Healthcare Group in March 2026, Dolon operates as a dedicated Value, Pricing and Access practice within the Prescient organization.
Differentiator
Problem solved
Functional benefit
Products and services
- Value Strategic value development service that turns complex clinical and evidence landscapes into high-impact value strategies, bridging clinical promise and reimbursement reality for rare disease and oncology medicines. Targeted at pharmaceutical and biotechnology companies seeking evidence-based value narratives.
- Access Global payer pathway advisory service that guides biopharma clients through access environments to ensure launch readiness and deliver treatments to patients who need them. Focused on rare disease and oncology launches.
- Pricing Pricing strategy consulting service that helps biopharma clients navigate pricing complexity with confidence, crafting robust and communicable price strategies credible from the boardroom to the negotiating table, focused on rare disease and oncology products.
- Market Access Policy Market access policy advisory that identifies policy imperatives for client portfolios and helps build compelling evidence, credible payer proposals, and stakeholder engagement strategies to drive positive access policy change within existing regulatory and reimbursement frameworks.
- Data & Analytics Data and analytics consulting service that turns data into decisions through advanced bespoke models, internal databases, and proprietary tools to define direction and influence outcomes for rare disease and oncology clients.
Quantifiable outcome
- 97% of projects delivered in rare diseases and oncology, with 12+ years of experience and 1,000+ successful engagements
- +1 more outcomes
Companies that use Dolon
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Dolon technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Dolon partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Prescient Healthcare GroupcorePrescient Healthcare Group acquired Dolon on 30 March 2026. Dolon will retain its specialist focus, joining as a dedicated Value, Pricing and Access practice working alongside Prescient's established teams. The partnership delivers seamless, comprehensive support for complex challenges, ensuring vital strategic pricing and market access insights inform pivotal decisions earlier and further across the product lifecycle. This follows Prescient's earlier acquisition of Uptake Strategies and is backed by investor Bridgepoint.
- Squire Patton BoggsminorSquire Patton Boggs served as legal advisor to Dolon and its shareholders in connection with the acquisition by Prescient Healthcare Group.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Dolon competitors and assessment
Company assessmentDirect peers
- LSC Life Sciences Consulting: A boutique consultancy serving biopharma on commercial strategy, market access, and pricing. Closely aligned with Dolon in size, therapeutic-area focus, and bespoke service model for pharmaceutical and biotech clients.
- Simon-Kucher & Partners: A global consulting firm with a strong life sciences pricing and market access practice. Directly comparable to Dolon in pricing strategy and value-based commercialization work, though with materially broader geographic and industry coverage.
- ClearView Healthcare Partners: A boutique life sciences strategy consultancy providing market access, pricing, and commercial insights to biopharma. Directly comparable to Dolon in therapeutic-area focus, specialist positioning, and bespoke delivery model.
- Putnam Associates: A specialist consulting firm focused on biopharma pricing, market access, and commercial strategy. Directly comparable to Dolon in service scope (pricing, access, value) and biopharma client base, with similar boutique positioning.
- Trinity Life Sciences: A life sciences strategy and insights consultancy offering market access, pricing, evidence, and commercial services to biopharma. Closely comparable to Dolon in therapeutic-area depth, pricing and access advisory, and project-based delivery model, though considerably larger in scale.
Broad incumbents
- IQVIA: A global life sciences services and data platform that includes pricing, market access, and HEOR consulting alongside its broader commercial and R&D offerings. Comparable to Dolon in service categories, but operates at vastly greater scale and with a technology/data-led model.
- Evidera (PPD / Thermo Fisher Scientific): A HEOR, market access, and real-world evidence consultancy serving biopharma. Comparable to Dolon in access and evidence work, but operating as part of a large CRO platform with broader R&D and data services.
- Charles River Associates (CRA): A global consulting firm with a Life Sciences practice providing pricing, market access, and commercial strategy support to biopharma. Comparable to Dolon in service overlap, but a significantly larger and more diversified practice across industries.
- McKinsey & Company (Pharma & Medical Products): A global management consultancy with a large Pharma & Medical Products practice delivering pricing, market access, and commercial strategy work. Overlaps with Dolon at the high end of pharma pricing and access engagements, but as a generalist powerhouse with vastly greater resources.
- ZS Associates: A large global consulting firm with a deep pharma and biotech practice spanning commercial, pricing, market access, and data analytics. Overlaps with Dolon in pricing and access advisory but operates at a much larger scale and with proprietary analytics platforms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Dolon social profiles
Digital presenceDolon compliance and trust
Trust signalCompliance1 record
Dolon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dolon leadership team
Management profileNumber of profiles
Dolon funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dolon M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dolon
What does Dolon do?
Dolon is an independent consultancy specializing in strategic pricing and market access for pharmaceutical and biotechnology companies developing rare disease and oncology medicines. The firm delivers five integrated service lines — Value, Access, Pricing, Market Access Policy, and Data & Analytics — through bespoke, project-based engagements that turn complex clinical and reimbursement landscapes into actionable strategies. Following its March 2026 acquisition by Prescient Healthcare Group, Dolon operates as a dedicated Value, Pricing and Access practice serving biopharma clients globally.
Is Dolon a public or private company?
Dolon is a private company. It is classified as corporate owned and is currently acquired.
When was Dolon founded?
Dolon was founded in 2013. It employs 11 to 50 people.
Where is Dolon based?
Dolon is headquartered in London, United Kingdom, in the Europe region.
How does Dolon make money?
One revenue line is on record: strategic Consulting Services.
Who are Dolon's main competitors?
Direct peers on record are LSC Life Sciences Consulting, Simon-Kucher & Partners, ClearView Healthcare Partners, Putnam Associates and Trinity Life Sciences. Broad incumbents are IQVIA, Evidera (PPD / Thermo Fisher Scientific), Charles River Associates (CRA), McKinsey & Company (Pharma & Medical Products) and ZS Associates.
Does Dolon have an API?
No public API is recorded for Dolon.